Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives $83.25 Average Target Price from Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report) has earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target […]
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report) has earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target […]
